文献速递乳房整形与再造

氨甲环酸与植入物乳房重建术后血肿和血清肿风险:1782例回顾性研究

Tranexamic Acid and the Risk of Hematoma and Seroma Following Implant-Based Breast Reconstruction: A Retrospective Study of 1782 Patients.
PubMed 文献 · Aesthet Surg J · 2025-01-01

该回顾性研究纳入2010至2023年间3个整形外科部门接受植入物乳房重建的1782例患者,其中352例术中接受静脉氨甲环酸(TXA)。多变量分析显示TXA与血肿(HR 0.81;结论认为TXA的临床效果有限,需未来研究进一步确定。

要点

  • 术中静脉TXA与植入物乳房重建后血肿和血清肿风险降低无显著关联。
  • TXA组血肿出现时间和拔管时间显著延长,但出院时间显著缩短。
  • TXA在该人群中的临床效果有限,需未来研究进一步验证。

核心结论

  • 术中静脉TXA与植入物乳房重建后血肿和血清肿风险降低无显著关联,临床效果有限。

研究设计与样本

  • 回顾性研究,纳入2010至2023年间3个整形外科部门接受植入物乳房重建的1782例患者,其中352例接受术中静脉TXA。
  • 采用稳健多变量Cox回归并结合逆概率治疗加权比较TXA组与非TXA组血肿和血清肿风险。

临床怎么用

  • 术中静脉TXA不应常规用于植入物乳房重建以期望降低血肿或血清肿风险。
  • 使用TXA时需注意血肿出现时间和拔管时间可能延长,但出院时间可能缩短。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素。
  • TXA组样本量相对较小(352例),需未来研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraoperative tranexamic acid (TXA) is used increasingly during implant-based breast reconstruction to reduce hematoma and seroma formation. However, evidence supporting the effectiveness of TXA in this setting remains limited. OBJECTIVES: The authors of this study aim to compare the risk of hematoma and seroma in patients treated with and without intraoperative intravenous TXA during implant-based breast reconstruction. METHODS: Medical records of patients who underwent breast reconstruction at 3 plastic surgical departments between 2010 and 2023 were retrospectively reviewed. We compared the risk of hematoma and seroma between patients treated with and without intraoperative intravenous TXA using robust multivariable Cox regression with inverse probability of treatment weighting. RESULTS: We included 1782 patients who underwent implant-based breast reconstruction, of whom 352 received intraoperative intravenous TXA. A multivariable analysis showed a nonsignificant reduction in the risk of hematoma (hazard ratio [HR] 0.81; P = .51) and seroma (HR 0.88; P = .68) in patients who received TXA. Furthermore, the time to hematoma was significantly longer (2 vs 1 day, P = .03), as well as the time to drain removal (7 vs 6 days, P < .001) for patients treated with TXA. However, the time to discharge was significantly shorter (4 vs 5 days, P < .001). CONCLUSIONS: Intraoperative administration of TXA was associated with a nonsignificant reduction in the risk of hematoma and seroma, suggesting a limited clinical effect in patients undergoing implant-based breast reconstruction. However, future studies are needed to definitively determine the effects in implant-based breast reconstruction.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Norlin CB, Weltz TK, Bak EEF, et al. Tranexamic Acid and the Risk of Hematoma and Seroma Following Implant-Based Breast Reconstruction: A Retrospective Study of 1782 Patients. Aesthet Surg J. 2025. PMID: 40795824. doi:10.1093/asj/sjaf154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。